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Abstract
Background: Soluble urokinase-type plasminogen activator receptor (suPAR) has emerged as a new sepsis biomarker.
It is not known whether suPAR has a role in critically ill patients with severe acute kidney injury (AKI).
Methods: Our main aims were to describe serial serum suPAR concentrations in patients with severe AKI, to investigate a
potential association between suPAR and C-reactive protein (CRP), and to compare suPAR and CRP as diagnostic markers
of infection in patients with AKI. Between April 2013 – April 2014, we recruited adult patients (≥18 years) with AKI KDIGO
stage 2/3 admitted to a multidisciplinary Intensive Care Unit (ICU) in a University Hospital in UK. Serial serum suPAR and
CRP concentrations were measured for 6 days. We compared the characteristics and serial suPAR and CRP concentrations
of patients with and without an infection using Chi-squared, Fisher’s exact, t-test and Mann-Whitney tests as appropriate,
and calculated the area under the receiver operating characteristics curve (AUC).
Results: Data of 55 patients with AKI stage 2/3 were analysed (62% male; mean age 60.5) of whom 43 patients received
continuous renal replacement therapy. suPAR was not detectable in effluent fluid.
There was no significant correlation between daily suPAR and CRP concentrations. In patients with an infection, suPAR
results were significantly higher than in those without an infection across all time points; there was no significant difference
in CRP levels between both groups. After exclusion of patients with an infection before or on day of admission to ICU, the
AUC of suPAR for predicting an infection later was 0.62 (95% CI 0.43–0.80) compared to 0.50 (95% CI 0.29–0.71) for CRP.
Conclusions: In critically ill patients with AKI stage 2/3, suPAR is a better marker of infection than CRP.
Trial registration: The study was retrospectively registered on the ISRCTN registry on 25 November 2012
(ISRCTN88354940).
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Background
Acute kidney injury (AKI) affects > 50% of patients in
the intensive care unit (ICU) [1]. It is associated with an
increased risk of complications and mortality. Sepsis is
particularly common but can be challenging to diagnose
due to potentially misleading clinical signs and a limited
number of confirmatory diagnostic tests in routine clin-
ical practice [2].
Over 150 sepsis biomarkers have been identified [3].
C-reactive protein (CRP) is used mainly as a marker of
inflammation. Measuring and charting CRP values can
prove useful in determining disease progress or the effect-
iveness of treatments but it has limited ability to distin-
guish sepsis from other inflammatory conditions [3, 4].
Soluble urokinase-type plasminogen activator receptor
(suPAR) is one of several newer sepsis markers that has
been investigated in recent years [5–8]. SuPAR is the
soluble form of the cell membrane-bound urokinase
plasminogen activator receptor (uPAR) which is expressed
on various cell types, including neutrophils, lymphocytes,
monocytes, endothelial cells and tumour cells. After cleav-
age from the cell surface, suPAR is released into the blood
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and most human body fluids. When inflammatory cells
are activated by cytokines, the expression of uPAR is
up-regulated, thus increasing the serum levels of suPAR,
too [9].
Several studies have shown higher systemic suPAR
concentrations in critically ill patients compared to
healthy controls, and in patients with infections com-
pared to those without [5, 7, 8, 10]. However, a system-
atic review of relevant papers published until May 2011
reported that the diagnostic value of suPAR was low in
critically ill patients with sepsis [11]. A subsequent
meta-analysis in 2016 concluded that suPAR had a role
as a biomarker for the diagnosis and prognosis of bacter-
ial infections but was relatively ineffective for differenti-
ating sepsis from systemic inflammation [12]. Both
meta-analyses were limited by inclusion of heterogenous
patient populations with varying acute and chronic ill-
nesses. Whether there is a role for suPAR in critically ill
patients with AKI is unknown.
Methods
Aims
The aims of our study were: a) to describe serial systemic
suPAR values in patients with severe AKI, including pa-
tients on continuous renal replacement therapy (CRRT);
b) to explore whether suPAR was removed during CRRT;
c) to investigate a potential association between suPAR
and CRP, and d) to compare suPAR and CRP as diagnostic
markers of infection in patients with AKI.
Design
We performed a prospective observational study be-
tween April 2013 and April 2014.
Setting
Guy’s & St Thomas’ NHS Foundation Hospital is a ter-
tiary care centre with a 43-bed, level 3 multi-disciplinary
adult intensive care unit (ICU).
Patient population
We recruited critically ill adult patients (≥18 years) with
AKI stage 2 or 3 as per serum creatinine criteria of the
Kidney Disease Improving Global Outcome classification
[13]. The lowest serum creatinine in the preceding
12 months prior to hospitalisation was used as a baseline
value; if not available, patients were excluded. Other
exclusion criteria were: AKI stage 2/3 present for more
than 36 h, pre-existing dialysis dependent renal failure,
or an expected life expectancy < 48 h. We also excluded
patients in whom serial blood sampling was not desir-
able (ie. Jehovah’s witness, patients with haemoglobin
< 70 g/L).
Collection of samples
Samples for serum suPAR were collected at baseline and
22-26 h, 46-50 h, 94-98 h and 142-146 h after enrol-
ment. Serum CRP was measured daily throughout the
6-day study period. In patients receiving CRRT, effluent
samples were collected at the same time points for
measurement of suPAR. All samples were processed and
stored in dedicated research freezers at -80 °C until
batch analysis at the end of the study.
Collection of clinical data
We collected baseline demographics, Acute Physiology
and Chronic Health Evaluation (APACHE) II score and
Sequential Organ Failure Assessment (SOFA) score on
admission to ICU. Patients were categorised as having
an infection if they had documented clinical signs com-
bined with positive microbiology or imaging results sup-
porting the diagnosis of an infection.
Laboratory analyses
Serial suPAR concentrations were measured by enzyme-
linked immunosorbent assay (ELISA) using the commer-
cially available suPARnostic® ELISA Kit manufactured by
ViroGates, Denmark. Samples were tested in singlets
with inter-plate variation of 6%. CRP was measured
using a latex enhanced immunoturbidimetric method on
the Siemens Advia 2400 [analytical range: 4–336 mg/L
and reference range: < 10 mg/L].
Statistics
Patient characteristics, suPAR and CRP levels were sum-
marised as frequency (percentage), mean [standard devi-
ation (SD)] or median [interquartile range (IQR)], as
appropriate. The relationship between suPAR and CRP
at each time point was explored using Pearson correl-
ation. Additionally, the correlations between suPAR and
previous day CRP, CRP and previous day suPAR, and
changes of suPAR and CRP from their respective previ-
ous measurement were calculated.
We compared the characteristics of patients who did
and did not develop infections using the Chi-squared,
Fisher’s exact and t-tests, as approriate. SuPAR and CRP
levels of both groups were compared using Mann-Whit-
ney tests, and areas under the receiver operating charac-
teristics curves (AUC) were calculated to assess the
ability of suPAR and CRP to discriminate between pa-
tients with an established infection and those who did
not develop an infection during the study period.
Results
We analysed the data of 55 patients with AKI stage 2 or
3 of whom 43 received CRRT during the 6-day study
period. The mean age was 60.5 (15.9) years and 61.8%
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were male (Table 1). The majority were caucasian (60%),
followed by Afro-Carribean (16.4%) and Asian (10.9%).
Biomarker results
Mean CRP levels increased between day of recruitment
and day 1 and then declined from day 3 onwards (Table 2
and Fig. 1). In contrast, the systemic suPAR levels
tended to remain stable or increase slighty across the
6-day study period (Table 2 and Fig. 2). In patients
treated with CRRT, suPAR was not detectable in the ef-
fluent fluid.
Correlation between suPAR and CRP
On the day of enrolment (ie. day 0), there was a weak to
moderate correlation between systemic suPAR and CRP
concentrations (r = 0.234) but this was not statistically
significant (p = 0.095) (Table 2 and Fig. 3). After day 0,
there was no significant correlation between CRP and
suPAR results.
To allow for the possibility that CRP or suPAR con-
centrations changed at different rates, the correlations
between values on consecutive days were calculated. No
significant correlation between CRP and suPAR concen-
trations was detected (Table 3). However, when evaluat-
ing the change in suPAR and CRP values from the
respective previous measurement, a weak correlation
between change in suPAR and CRP from day 0 to day 1
(r = 0.298, p = 0.037) and day 1 to day 2 (r = 0.310, p =
0.029) was noted (Table 3). There was no correlation at
any later time point.
Role of suPAR and CRP as markers of infection
There were no significant baseline differences between
patients with and without an infection during the 6-day
study period (Table 4). Values of suPAR were signifi-
cantly higher in those with an infection across all time
points but there was no difference in CRP results
(Table 5). In patients with an infection, the respective
AUCs of suPAR on the day of infection were higher than
those of CRP values (Table 6).
Role of suPAR and CRP as predictors of infection
The majority of infections were diagnosed before of
shortly after admission to the ICU. Thirty six patients
had an infection during the study period of whom 5
(13.9%) were diagnosed prior to enrolment and 13 (36%)
on day of enrolment; the remaining 18 patients (50%)
were diagnosed later. Following exclusion of patients
with an infection before or on day of ICU admission, the
AUC of suPAR on day 0 for predicting an infection later
was 0.62 (95% CI 0.43–0.80) compared to 0.50 (0.29–
0.71) for CRP.
Table 1 Baseline demographics
Parameter Total cohort (n = 55)
Age [years], mean (SD) 60.5 (15.9)
Male gender, n (%) 34 (61.8%)
Ethnicity
Caucasian 60%
Afro-Caribbean 16.4%
Asian 10.9%
Other 12.7%
Diabetes Mellitus 18 (32.7%)
Any CKD 19 (34.6%)
CKD stages
1 0
2 2 (3.6%)
3a 7 (12.7%)
3b 7 (12.7%)
4 2 (3.6%)
5 1 (1.8%)
ICU admission diagnosis, n (%)
Post-major surgery 19 (34.5%)
Sepsis 16 (29%)
Respiratory failure 6 (10.9%)
Vasculitis 2 (3.6%)
Multi-organ failure 4 (7.2%)
Neurological emergency 2 (3.6%)
Cardiac arrest 1 (1.8%)
Other 5 (9.1%)
Severity of illness on admission to ICU
APACHE II score, mean (SD) 19.4 (5.2)
SOFA score, mean (SD) 8.1 (2.4)
Abbreviations: APACHE Acute Physiology and Chronic Health Evaluation, CKD
chronic kidney disease, SD standard deviation, SOFA sequential organ failure
assessment, ICU Intensive care unit
Table 2 Correlations between mean systemic suPAR and CRP
values
suPAR [ng/ml]
mean (SD)
CRP [mg/L]
mean (SD)
Correlation
Day of enrolment 11.0 (7.6) 176.0 (113.2) r = 0.234 p = 0.095
Day 1 11.7 (7.7) 199.5 (106.0) r = 0.092 p = 0.519
Day 2 12.5 (8.9) 195.5 (105.6) r = 0.018 p = 0.897
Day 3 – 160.2 (88.5)
Day 4 12.6 (9.0) 142.3 (88.0) r = 0.012 p = 0.935
Day 5 – 126.1 (80.6)
Day 6 13.4 (9.0) 115.6 (74.2) r = 0.039 p = 0..801
Abbreviations: suPAR soluble urokinase-type plasminogen activator receptor,
CRP C-reactive protein, r regression, SD standard deviation
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Discussion
Our results show that CRP was a poor marker of infec-
tion in patients with severe AKI whereas suPAR had a
stronger association with the development of an infec-
tion. We also confirmed that serum suPAR was not
removed during CRRT.
Infections are the major causes of morbidity and mor-
tality in patients with AKI [14]. Accurate and timely
diagnosis is essential to enable clinicians to initiate
appropriate and effective antimicrobial therapy early.
The tools used by clinicians, namely clinical signs,
inflammatory markers and imaging techniques, have
important limitations [15].
SuPAR has emerged as a potential sepsis biomarker [2, 5,
6]. Under normal physiological conditions, suPAR is pre-
dominantly expressed by neutrophils, monocytes, macro-
phages and activated T-cells, and its serum concentration is
relatively stable throughout the day [9]. In healthy adults,
mean suPAR concentrations of 2000 pg/ml have been
reported [16]. SuPAR has a molecular mass of approxi-
mately 55-60 kDa. While the membrane-bound uPAR
appears to facilitate phagocytosis of bacteria, suPAR
has chemotactic properties and facilitates recruitment
of neutrophils and monocytes [8, 11, 17, 18]. Apart
from infections, serum concentrations of suPAR may
also be increased during inflammatory conditions, such as
Fig. 1 Serial serum CRP concentrations. Abbreviations: CRP = C-reactive protein
Fig. 2 Serial systemic suPAR concentrations. Abbreviations: suPAR = soluble urokinase-type plasminogen activator receptor
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arthritis, cancer and liver disease [9]. Not surprisingly,
several studies have shown that critically ill patients with
systemic inflammatory response syndrome (SIRS),
bacteraemia or sepsis had significantly higher suPAR
results than healthy controls but the accuracy of
suPAR to differentiate sepsis from SIRS was low
[5, 12, 19–22].
Data on the role of suPAR in patients with renal
disease are limited to patients with specific types of
chronic kidney disease (CKD) like focal segmental glo-
merulosclerosis, diabetic nephropathy and lupus neph-
ritis where plasma suPAR appears to have a pathological
role resulting in proteinuria and renal scarring [23–26].
In a recent prospective observational trial in 107 con-
secutive elective cardiac surgery patients, suPAR levels
were predictive of the development of AKI after surgery
after exclusion of patients with pre-existing CKD [27].
Finally, in patients with cardiovascular risk factors,
suPAR levels have been found to be associated with a
more rapid decline in glomerular filtration rate [23].
This is the first study that focused on the role of
suPAR as a marker of infection in patients with severe
AKI. The main result was that suPAR only had moderate
sensitivity and specificity but performed better than
CRP. This is an important finding since CRP is often
used in clinical practice as an aid to diagnose and moni-
tor the course of an infection. We acknowledge that
further research is necessary to confirm these findings. It
will also be important to compare the performance of
suPAR with that of procalcitonin (PCT), and to evaluate
Fig. 3 Scatter plots of daily suPAR and CRP values. Abbreviations: suPAR = soluble urokinase-type plasminogen activator receptor in ng/ml; CRP =
C-reactive protein in mg/L
Table 3 Correlations between systemic suPAR and CRP values
on different days
Correlation between
suPAR result and
previous day CRP
value
Correlation between
CRP value and
previous day suPAR
result
Correlation between
change in suPAR and
change in CRP values
Day 1 r = 0.228 p = 0.108 r = 0.042 p = 0.767 r = 0.298 p = 0.037
Day 2 r = − 0.026 p = 0.856 r = 0.090 p = 0.518 r = 0.310 p = 0.029
Day 3 – r = − 0.104 p = 0.491 –
Day 4 r = − 0.049 p = 0.747 – r = 0.232 p = 0.129
Day 5 – r = 0.036 p = 0.819 –
Day 6 r = 0.048 p = 0.761 – r = −0.166 p = 0.299
Abbreviations: suPAR soluble urokinase-type plasminogen activator
receptor, CRP C-reactive protein, r regression
Table 4 Characteristics of patients with and without infection
Parameter No infection during
6-day study period
n = 19
Infection during
6-day study period
n = 36
p-value
Age, mean (SD) 61.5 (16.7) 60.0 (15.7) 0.75
Male sex, n (%) 12 (63.2) 22 (31.1) 0.88
Ethnicity, n (%)
Caucasian 11 (57.9) 22 (61.1) 0.69
Afro-Carribean 4 (21.1) 5 (13.9)
Asian 1 (5.3) 5 (13.9)
Other 3 (15.8) 4 (11.1)
BMI, mean (SD) 27.4 (5.5) 29.2 (8.9) 0.46
SOFA score on
admission to ICU,
median (IQR)
8 (7–10) 8 (7–9) 0.43
Diabetes Mellitus 4 (21.1) 14 (38.9) 0.23
Any CKD 7 (36.8) 12 (33.3) 0.99
Abbreviations: BMI body mass index, ICU intensive care unit, IQR interquartile
range, SD standard deviation
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the role of suPAR in combination with existing severity
of illness scores.
We acknowledge other potential limitations. First, as a
single centre study, there is reduced generalisability of the
results to centres with a different patient-case mix. Sec-
ond, we categorised patients as having an infection based
on a retrospective review of all clinical data, laboratory re-
sults and microbiological reports. It is possible that pa-
tients with an infection were missed or mis-classified.
Third, suPAR concentrations can be affected by other in-
flammatory conditions, cancer and liver disease. In our
analysis, we did not control for these potential con-
founders. Fourth, we only enrolled patients with AKI stage
2 and 3 and did not distinguish between different types
and aetiologies of AKI, and it is possible that the perform-
ance of suPAR varies depending on the aetiology or stage
of AKI. Finally, our sample size was relatively small. Lar-
ger studies are necessary to validate our findings, to deter-
mine a diagnostic cut-off of suPAR in patients with AKI
and to explore whether suPAR levels correlate with the
clinical course following an infection.
Conclusions
Our study showed that suPAR concentrations had better
diagnostic and predictive value than CRP to detect infec-
tions in critically ill patients with severe AKI. Larger
studies are necessary to confirm our findings.
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No infection during 6 day
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n Median (IQR) n Median (IQR) n Median (IQR) n Median (IQR)
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Table 6 Area under the receiver operating curves of suPAR and
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suPAR CRP
n AUC 95% CI n AUC 95% CI
Day 0 43 0.73 0.57–0.89 40 0.58 0.39–0.77
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operating characteristics curve
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